Bioinformatics Center - BIC, ACBR

ACBR is accepting applications for a P.G. Diploma in Bioinformatics, Computational Biology & Drug Discovery for the session 2025-2026. The last date to apply is 21st July 2025. Details available at the ACBR website: http://acbrdu.edu/

~One more significant contribution from Bioinformatics Centre-ACBR~
--------------------------------------------------------------------------
Team of researchers from Bioinformatics Centre ACBR, University of Delhi , Unveil Curcumin's Potential as Inhibitor Against SARS-CoV-2 Variants' Spike Protein Interaction
--------------------------------------------------------------------------
In the ongoing efforts to find a remedy for the SARS CoV2 pathogen, researchers from the Dr. B R Ambedkar Center for Biomedical Research (ACBR), University of Delhi, led by Prof. Daman Saluja and Prof. Madhu Chopra, have unveiled significant findings published in the Journal of Biomolecular Structure & Dynamics. Their study focused on the structure-based drug discovery, specifically targeting inhibitors for the interaction between the SARS-CoV-2 spike protein and ACE2 receptors.

The research article, first authored by Dr. Ravi Kant and with significant contributions from Dr. Rahul Kaushik from the Technology Innovation Institute in Abu Dhabi, delved into an exhaustive investigation. Their prime focus was to uncover the potential of natural compounds that possess the property to thwart the interaction between the receptor binding domain (RBD(S1)) and human angiotensin-converting enzyme 2 (hACE2) domains, particularly within the Delta and Omicron variants.

Since the emergence of the COVID-19 pandemic, the virus has undergone dynamic evolutionary changes, resulting in a myriad of variants categorized by the World Health Organization (WHO) as variants of interest (VOI), variants under monitoring (VUM), and variants of concern (VOC). Notably, five VOCs (Alpha, Beta, Delta, Gamma, and Omicron) and additional VOIs have been reported globally, necessitating targeted and adaptable therapeutic approaches.

The team's research centers around Curcumin, a natural compound that exhibited promising inhibitory potential against the RBD(S1)-hACE2 interaction, particularly for the Delta and Omicron variants. Employing cutting-edge computational methodologies, their study presented compelling evidence showcasing Curcumin's efficacy in hindering these interactions compared to other lead compounds.
What's especially intriguing is the team's exploration of how mutations in the RBD(S1) of VOCs, specifically the Delta and Omicron variants, significantly impact the structure of the Spike protein, altering its binding affinity to the hACE2 receptor. Molecular docking and Molecular Dynamics (MD) simulations provided substantial support for the stability of the docked complexes, reinforcing the study's findings.

This innovative research marks a crucial step forward in understanding the interplay between SARS-CoV-2 variants and potential therapeutic interventions. It lays a solid foundation for further investigations into how these structural alterations influence drug molecules' efficacy and their potential therapeutic impact in vivo.

These findings hold immense promise in the ongoing battle against COVID-19, offering a potential avenue for the development of targeted therapies and interventions tailored to combat the evolving landscape of SARS-CoV-2 variants.

Prof. Madhu Chopra recently served as a judge for the oral sessions at the International Conference hosted by St. Stephen's College. Her expertise and discernment contributed to the scholarly discourse, fostering excellence and innovation in academic research.

Prof. Madhu Chopra shared her insights at the International Conference on Integrative Science organized by Deshbandhu College. Her talk illuminated the intersection of diverse scientific disciplines, fostering collaboration and innovation for a brighter future.

Prof. Madhu Chopra recently conducted hands-on training sessions on molecular docking at GLA University, providing students with invaluable practical skills in computational drug discovery. With her guidance, the next generation of researchers is poised to make impactful contributions to the field.

🌟 Dr. Ravi Kant delivered an oral talk on "Computational Drug Discovery" at an International Conference held in Cape Town-South Africa!
🧬✨ Thanks to The Bill & Melinda Gates Foundation, this vital discussion on identifying novel small molecule inhibitors against Neisseria gonorrhoeae was fully funded.
💡🔬 Let's continue supporting innovative research for global health!
🌍💪
RaviKant Sharma University of Delhi

Prof. Madhu Chopra recently shared her expertise in drug discovery with a captivating talk at Manav Rachna International Institute of Research and Studies. Her insights into the latest trends and methodologies are shaping the future of pharmaceutical research.

Prof. Madhu Chopra recently delivered an insightful lecture on "Paradigm Shift in Techniques for Computer-Aided Drug Design and Development" at Shoolini University as part of the DST-STUTI program. Delve into the latest advancements in drug discovery by reading more about the event in this news article: Read more
University of Delhi Delhi university Info.

🌟**Celebrating Academic Excellence!**🌟

We are thrilled to share the outstanding achievement of Ms. Vineeta Teotia from Prof. Madhu Chopra Lab, who recently presented her groundbreaking Ph.D. work on the design and development of CDK1 inhibitors as Anti-Cancer compounds at the prestigious ESMO-TAT 2024 (European Society of Medical Oncology-Targeted Anticancer Therapies 2024) conference in Paris, France.

🔬 Vineeta's research represents a significant contribution to the field of cancer therapeutics, offering promising insights into potential treatments for combating this challenging disease. Her dedication, expertise, and innovative approach have garnered attention and accolades on an international platform, highlighting the caliber of research emerging from our lab.

🎓 As Vineeta continues to excel in her academic and research endeavors, we extend our heartfelt congratulations and best wishes for her continued success. Her achievements inspire us all and underscore the importance of collaboration, innovation, and perseverance in advancing scientific knowledge and improving patient outcomes.

👏 Join us in applauding Vineeta for her exceptional presentation at ESMO-TAT 2024 and wishing her continued success in her future endeavors!

🎓🔬👩‍🔬

University of Delhi Delhi university Info.

🎓 **Celebrating Success at the 100th Convocation of the University of Delhi!** 🎓

We are immensely proud to congratulate four exceptional individuals, Dr. Priya Poonia, Dr. Sumeet Kaur, Dr. Ravi Kant, and Dr. Prakash Jha, who have successfully utilized the Bioinformatics Facility in their research journeys and have been awarded their Ph.D. degrees in Biomedical Science at the 100th Convocation of the University of Delhi.

🌟 Their dedication, perseverance, and scholarly contributions have not only enriched the academic landscape but have also propelled the boundaries of knowledge in the field of biomedical science. Their research, supported by the innovative tools and resources of the Bioinformatics Facility, stands as a testament to their commitment to excellence and the pursuit of scientific advancement.

🔬 As they embark on the next phase of their careers, we extend our heartfelt congratulations and best wishes for continued success and impact. May their accomplishments inspire future generations of researchers and contribute to the collective pursuit of knowledge and discovery in biomedical science.

👏 Join us in applauding Dr. Priya Poonia, Dr. Sumeet Kaur, Dr. Ravi Kant, and Dr. Prakash Jha for their outstanding achievements and wishing them continued success in their future endeavors!

🌱🎉👩‍🎓👨‍🎓

University of Delhi Delhi university Info. RaviKant Sharma Prakash Jha

🌟 Celebrating Student Achievements! 🌟

We are delighted to announce that one of our outstanding students from the first batch of our PG Diploma Program in Bioinformatics, Computational Biology, and Drug Discovery, Ms. Roquiya Tazeen Fatima, has been selected for the prestigious International Master in Sustainable Drug Discovery along with an Erasmus Mundus scholarship!

🎓 This incredible achievement is a testament to her hard work, dedication, and exceptional talent. It showcases the quality of education and training provided by our program and highlights the caliber of our students.

🌍 As she embarks on this exciting new chapter in her academic journey, we extend our warmest congratulations and best wishes for her continued success. We have no doubt that Roquiya will excel in her endeavors and make meaningful contributions to the field of sustainable drug discovery.

👏 Join us in celebrating this remarkable accomplishment and wishing Roquiya the very best as she pursues her dreams on the global stage!

🌱🎉📚

University of Delhi Delhi university Info.